To monitor delivered dose and trigger plan adaptation when deviation becomes unacceptable, a clinical treatment dose (Tx-Dose) reconstruction system based on three-dimensional (3D)/four-dimensional (4D)-cone beam computed tomograpy (CBCT) images was developed and evaluated on various treatment sites, particularly for lung cancer patient treated by stereotactic body radiation therapy (SBRT). This system integrates with our treatment planning system (TPS), Linacs recording and verification system (R&V), and CBCT imaging system, consisting of three modules: To take full advantage of the valuable information carried by 4D-CBCT, a novel phase-matching DIR scheme was developed to generate 4D pseudo-CT images for 4D dose reconstruction. Finally, TDR module creates TPS scripts to automate TxDose calculation on the pseudo-CT images. Both initial quantitative commissioning and patient-specific qualitative quality assurance of the DIR tool were utilized to ensure the DIR quality. The treatment doses of ten patients (six SBRT-lung, two head and neck (HN), one breast and one prostate cancer patients) were retrospectively constructed and evaluated. The target registration error (mean ± STD:
the treatment progress in the R&V system and triggers the PCG module when new CBCT is available. PCG retrieves the CBCTs and performs planning CT to CBCT deformable registration (DIR) to generate pseudo-CT. The 4D-CBCT images are taken for target localization and correction in lung cancer patient before treatment.
To take full advantage of the valuable information carried by 4D-CBCT, a novel phase-matching DIR scheme was developed to generate 4D pseudo-CT images for 4D dose reconstruction. Finally, TDR module creates TPS scripts to automate TxDose calculation on the pseudo-CT images. Both initial quantitative commissioning and patient-specific qualitative quality assurance of the DIR tool were utilized to ensure the DIR quality. The treatment doses of ten patients (six SBRT-lung, two head and neck (HN), one breast and one prostate cancer patients) were retrospectively constructed and evaluated. The target registration error (mean ± STD:
1.05 ± 1.13 mm) of the DIR tool is comparable to the interobserver uncertainty (0.88 ± 1.31 mm) evaluated by a publically available lung-landmarks dataset. For lung SBRT patients, the D 99 of the final cumulative Tx-Dose of GTV is 93.8 ± 5.5% (83.7-100.1%) of the originally planned D 99 . CTV D 99 decreases by 3% and mean ipsilateral parotid dose increases by 11.5% for one of the two HN patients. In conclusion, we have demonstrated the feasibility and effectiveness of a treatment dose verification system in our clinical setting.
| INTRODUCTION
Treatment delivered dose in patient could vary from the planned one due to patient setup, target motion, and anatomic variation. 1, 2 For lung cancer treatment, the percentage of ITV volume changes of a cohort of 40 Stereotactic Body Radiation Therapy (SBRT) lung patients were reported to range from −59.6% to 13.0% (−21.0 ± 21.4%) at the end of treatment. 3 The anatomic change caused by atelectasis, pleural effusion, and pneumonia could also significantly affect the dose distribution. 4, 5 In addition, the breathing pattern variations during treatment in magnitude, period, and mean position could negatively impact the delivered dose. 6 For head and neck cancer patient, Vasquez Osorio et al. reported that the primary tumor shrunk by 25 ± 15% and the ipsilateral parotid grand by (20 ± 10%). 7 For radiotherapy in the pelvic and abdominal region, the organ filling and deformation, which may not be fully correctable by couch shifting, could lead to significant treatment dose deterioration of critical organs. [8] [9] [10] [11] [12] As a result, treatment dose assessment is a useful technique to monitor delivery accuracy for patients who may undergo notable tumor regression/progression or anatomy/motion variation.
A clinical treatment dose monitoring system can serve as an important infrastructure to support the radiotherapy treatment quality evaluation, adaptive radiation therapy decision-making, and treatment outcome modelling. 13, 14 For example, the reconstructed daily treatment dose can be utilized to monitor the target coverage and organ at risk (OAR) sparing during the delivery. The cumulative treatment dose from previously delivered fractions can be used to support plan adaptation decisions. 15 Among all the factors, patient anatomic variation during radiotherapy is considered to be the number one source of uncertainty for radiobiology modeling. 16 Therefore, the reconstruction of cumulative treatment dose based on CBCT could became a prerequisite for accurate treatment outcome modeling.
2,17
Numerous studies have demonstrated the feasibility of using CBCT to construct treatment dose for photon [18] [19] [20] [21] [22] [23] and recently for proton radiotherapy 24, 25 on various treatment sites. However, few such systems actually are running in real clinical routine due to various practical reasons. Three major obstacles could be the limited interoperability among different software systems in a specific clinical setting, the extra clinical workload for an already busy clinic and the concern of deformable image registration (DIR) uncertainty behind dose accumulation. [26] [27] [28] Ideally, such a system should integrate seamlessly with the existing treatment planning system, recording and verify system, and onboard imaging system. All the necessary information such as treatment plan, delivery schedule, and CBCT image should be retrieved automatically. Also, the clinical workflow should be as intuitive and automate as possible to minimize the extra clinical workload. Furthermore, as emphasized in the recently published AAPM Task Group report 132 (TG 132) , a convenient patient-specific quality assurance (QA) of DIR between CT and CBCT is essential to ensure the quality of pseudo-CT creation and treatment dose warping 29 .
Early stage non-small cell lung tumor could be difficult to identify on 3D-CBCT due to inferior image quality and motion artifact.
30,31
The 4D-CBCT technique has been widely adopted for daily imageguided alignment of moving targets. 32 Daily breathing pattern varia- A diagram illustrating the 4D-CBCT-based treatment dose reconstruction is shown in Fig. 3 . After the 4D-pseudo-CT is generated, the images are load into TPS to calculate doses on all ten phases. 
2.C | The clinical workflow
The clinical workflow as illustrated in A calendar GUI (Fig. 1 center) was designed to visualize the pro- 
2.D | The initial commissioning of the DIR tool for lung patient
It is difficult and time consuming to define corresponding landmarks for lung between CT and CBCT images. Instead, the landmarks on ten lung 4D-CT cases from a public dataset (www.dir-lab.com) were utilized to evaluate the accuracy of the DIR tool on lung region. 40, 41 Briefly, this dataset includes large numbers of evenly distributed landmark pairs (883.2 ± 507.7 per patient, 342-1561) identified on the end of inhale and exhale phases of the 4D-CT. The DIRs were conducted without any parameter tuning of our tool and the output DVFs were evaluated with ground truth by Target Registration Error (TRE). The TRE was then compared to the published result and the interobserver variability provided with the dataset on its website (last checked on 2018/05).
4D-CBCT has inferior quality and contains less structural details compared to 4D-CT. For example, some vessel and bronchial bifurcations that are visible on CT may not be identifiable on CBCT. Therefore, the DIR algorithm may not always be able to find corresponding objects on the CBCT. Using the CT-CT landmarks validation, we intended to validate how well the DIR algorithm could model the respiration process and match the visible features inside the lung. In addition, CT and CBCT intensity have strong correlation 42 and the LCC similarity metric employed in the final stage of the DIR is robust to this type of "modality transformation". 43 It also should be noted that the evaluation landmarks are defined on two extreme phases while the closest matching phases are chosen to minimize the difference before DIR in our application. Therefore, we believe the CT-CT validation results could serve as a surrogate for accuracy of the CT-CBCT DIR.
2.E | Evaluation on clinical patients
Ten recently treated patients (six lungs SBRT, two head and neck, one breast, and one prostate) were retrospectively selected. Lung patients were chosen based on their large excursion variation. The other patients were selected for their large anatomic variation during treatment. This group of patients represented a sample of the most challenging cases in our clinic. The tumor position/excursion, dose prescription, and fractionation of all patients are list in Table 1 3 | RESULTS The dose parameters representing target coverage for all ten clinical patients are listed in Table 1 . It should be noted that the plan doses of lung patients were recalculated on ten phases and accumulated to the reference phase (4D plan-dose). For all lung patients, the targets were well covered by the prescription dose as indicated by the GTV D 99 . Figure 6A(1-3) show the plan dose, final cumulative 4D Tx-dose, and DVH for lung patient 1. Only a slight difference was observed in the high-dose region inside the GTV (red color wash). The planned and final cumulative treatment doses of patient 6 are shown in Fig. 6B(1-3) . For this patient, the daily setup was very challenging with a small tumor and vessel bifurcations nearby.
Two out of five fractions were found to have inferior localization.
The target was covered by the prescription dose as shown in the final cumulative doses, but much different than the planned one (Fig. 6B3 ).
The variations of clinically relevant dose parameters of OAR are listed in Table 2 The planned and final cumulative dose are shown in Fig. 8A(1-3) for the prostate patient and Fig. 8B Patient-specific HU tables have been proposed for dose calculation on 3D CBCT with acceptable accuracy for lung cancer patient. 23 The HU/density table is generated by manually selecting the homogeneous areas of different tissues on both the CT and the CBCT, which is time consuming and error prone. And the HU variation and potential motion artifact of the CBCT could have more significant impact on dose calculation for lung regions with very low electron density. By utilizing 4D-CBCT with the phase-matching DIR scheme, the 4D treatment dose reconstruction should be a more suitable methodology for lung cancer patients, especially for SBRT delivery.
The newly published TG 132 recommends both quantitative and qualitative validation of the DIR tool for advanced clinical application like dose warping. 29 The QA of the DIR algorithm, which is the under-the-hood key technique of this system, was done in two steps. The first step is the initial quantitative commission with a publicly available lung landmark data set and expert-delineated contours.
The second step is the daily patient-specific qualitative assessment by fusion image and propagated contour. Currently, we set empirical thresholds for the volume change of target and solid critical organ (>10%) and for the translation of target center of mass (>3 mm).
Any variation over the preset threshold will trigger notification to user. The user will inspect the autopropagated contour on the CBCTs as well as the fusion images to determine the DIR quality. 
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